RecruitingPhase 3NCT05816226

Topical Treatment for TMJ Arthralgia

Comparison of Topical 1% Diclofenac and Topical 2.5% Hydrocortisone for TMJ Arthralgia


Sponsor

University of the Pacific

Enrollment

90 participants

Start Date

Jun 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to evaluate the efficacy of topical 2.5% hydrocortisone in TMJ arthralgia. The main questions it aims to answer are: * How does pain reduction compare? * How does improvement in jaw function limitation compare? * How do side effects compare? Participants will * On day 1 be examined and report their pain level and jaw function limitation * On days 1-21, apply their cream four times a day * On day 21, report their pain level, jaw function limitation, compliance with instructions, and side effects. Researchers will compare topical 2.5% hydrocortisone and topical 1% diclofenac to see if efficacy and side effects differ.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Arthralgia of at least 1 TMJ for at least 3 days

Exclusion Criteria6

  • Systemic pain condition
  • Past adverse reaction to steroid
  • Currently taking steroid
  • Taken steroid in the past \_\_\_ months
  • Muscle relaxants (may start after study is complete)
  • New night guard during study, or within 1 month of start of study (may start after study is complete)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHydrocortisone 2.5%

Applied four times daily to TMJ with arthralgia

DRUGDiclofenac 1% topical

Applied four times daily to TMJ with arthralgia


Locations(1)

Arthur A. Dugoni School of Dentistry, University of the Pacific

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05816226


Related Trials